ストックスクリーナーアプリを入手
18.44
1.60%
-0.30
Damora Therapeutics Inc (DMRA) 最新ニュース
Breaking News about Damora Therapeutics, Inc.Ordinary Shares (Nasdaq:DMRA) - FinancialContent
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares - Investing.com
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com South Africa
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com India
Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneDark Pool Volume - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesFear Greed Index - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesSuperTrend - careplusvn.com
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - kalkinemedia.com
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresQuarterly Earnings - vinanet.vn
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com UK
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com Australia
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com
DMRA Q2'26 Earnings: EPS estimate is (0.41) USD - TradingView
6.61%
0.00%
大文字化:
|
ボリューム (24 時間):